Alessandro Bellapianta
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Alessandro Bellapianta has a total of 24 co-authors. Here are the top co-authors by number of shared publications:
- Ahmad Salti
Research Group Cellular and Molecular Ophthalmology, University Clinic for Ophthalmology and Optometry, Johannes Kepler University Linz, Kepler University Hospital, Altenberger Strasse 69, 4040 Linz and Krankenhausstrasse 5, 4020 Linz, Austria
6 shared publications - Matthias Bolz
Department of Ophthalmology and Optometry, Kepler University Clinic, Linz, Upper Austria, Austria
5 shared publications - Sara Ouaidat
Research Group Cellular and Molecular Ophthalmology, University Clinic for Ophthalmology and Optometry, Johannes Kepler University Linz, Kepler University Hospital, Altenberger Strasse 69, 4040 Linz and Krankenhausstrasse 5, 4020 Linz, Austria
3 shared publications - Ana Cetkovic
Center for Medical Research, University Clinic for Ophthalmology and Optometry, Johannes Kepler University Linz, 4020 Linz, Austria
2 shared publications - Andrea Corna
Biomedical Electronics and Systems, Institute of Biomedical Electronics, Technische Universität Wien, Vienna, Austria
2 shared publications - Jingjing Qi
Tumor Epigenetics Laboratory, Johannes Kepler University Linz, Altenbergerstraße 69, 4040 Linz, Austria
2 shared publications
Latest Publications
- Open Access
- 24 December 2025
- Published by MDPI AG in Biomedicines
- Vol. 14 (1) , 45
Single-Cell Transcriptomics on PRPF31-Mutated Retinal Organoids Reveal Early Müller Glial Activation and Progressive Photoreceptor Degeneration
Background: Retinitis pigmentosa (RP) encompasses a group of inherited retinal disorders characterized by progressive degeneration of rod and cone photoreceptors, leading to vision loss. Among RP subtypes, RP11 is linked to mutations in PRPF31, a key spliceosome component, resulting in retinal cell dysfunction. Although PRPF31 is ubiquitously expressed, its mutations predominantly impact retinal cells, leading to the progressive loss of photoreceptors. Despite significant progress, studies have focused on photoreceptor and retinal pigment epithelium dysfunction in late disease stages, leaving early molecular events and the involvement of other retinal cell types unresolved. Moreover, comprehensive single-cell analyses capturing dynamic transcriptional changes across all retinal populations at early and late differentiation stages are still lacking. Methods: Using patient-derived retinal organoids (ROs), this study investigates the impact of PRPF31-RP11 mutation through a series of morphological, functional, molecular, and transcriptomics analyses. Results:. Single-cell RNA sequencing revealed dynamic gene expression related to early Müller glia activation, retinal ganglion cell distress, and progressive photoreceptor degeneration. Findings identify dysregulated molecular pathways associated with phototransduction, oxidative stress, and inflammation. Conclusions: Our results support a specific RO model of RP11 in which PRPF31 mutation recapitulate in vitro key features of RP, while simultaneously eliciting compensatory or modulatory responses in other retinal cell types.
- 24 December 2025
- Published by MDPI AG in Biomedicines
- Vol. 14 (1) , 45
Open AccessSingle-Cell Transcriptomics on PRPF31-Mutated Retinal Organoids Reveal Early Müller Glial Activation and Progressive Photoreceptor Degeneration
Background: Retinitis pigmentosa (RP) encompasses a group of inherited retinal disorders characterized by progressive degeneration of rod and cone photoreceptors, leading to vision loss. Among RP subtypes, RP11 is linked to mutations in PRPF31, a key spliceosome component, resulting in retinal cell dysfunction. Although PRPF31 is ubiquitously expressed, its mutations predominantly impact retinal cells, leading to the progressive loss of photoreceptors. Despite significant progress, studies have focused on photoreceptor and retinal pigment epithelium dysfunction in late disease stages, leaving early molecular events and the involvement of other retinal cell types unresolved. Moreover, comprehensive single-cell analyses capturing dynamic transcriptional changes across all retinal populations at early and late differentiation stages are still lacking. Methods: Using patient-derived retinal organoids (ROs), this study investigates the impact of PRPF31-RP11 mutation through a series of morphological, functional, molecular, and transcriptomics analyses. Results:. Single-cell RNA sequencing revealed dynamic gene expression related to early Müller glia activation, retinal ganglion cell distress, and progressive photoreceptor degeneration. Findings identify dysregulated molecular pathways associated with phototransduction, oxidative stress, and inflammation. Conclusions: Our results support a specific RO model of RP11 in which PRPF31 mutation recapitulate in vitro key features of RP, while simultaneously eliciting compensatory or modulatory responses in other retinal cell types.
- Open Access
- 2 November 2025
- Published by Wiley in Advanced Functional Materials
- Vol. 36 (23)
Near‐Infrared Organic Photovoltaic Electrodes for Subretinal Neurostimulation
Organic semiconductors are emerging as a promising class of photovoltaic materials for neural interfaces, offering high power conversion, mechanical flexibility, biocompatibility, and tunable optoelectronic properties. In this study, the application of a D18:Y6‐based organic photovoltaic (OPV) electrode is investigated for subretinal stimulation in a model of retinal degeneration. It is demonstrated that OPV devices can be engineered to electrically stimulate the retina via network‐mediated pathways, in a manner comparable to established neurostimulation approaches. The presented OPV electrodes reliably activate retinal ganglion cells, eliciting consistent spike responses to light pulses within the near‐infrared range. The stimulation onset, spike latency, and response profiles suggest effective faradaic charge injection as a key mechanism for neuronal activation, particularly for longer pulse durations. Moreover, it is shown that both light intensity and pulse duration can be used to finely tune the neural response, offering a high degree of control over retinal ganglion cell activation. Finally, it is proven that D18:Y6 blend is biocompatible in vitro when in direct contact with human induced pluripotent stem cell (iPSC)‐derived retinal organoids and mouse explants. These results validate the photo‐electrical performance and biocompatibility of D18:Y6 OPVs and position them as a viable candidate for next‐generation, minimally invasive retinal prosthetics.
- 2 November 2025
- Published by Wiley in Advanced Functional Materials
- Vol. 36 (23)
Open AccessNear‐Infrared Organic Photovoltaic Electrodes for Subretinal Neurostimulation
Organic semiconductors are emerging as a promising class of photovoltaic materials for neural interfaces, offering high power conversion, mechanical flexibility, biocompatibility, and tunable optoelectronic properties. In this study, the application of a D18:Y6‐based organic photovoltaic (OPV) electrode is investigated for subretinal stimulation in a model of retinal degeneration. It is demonstrated that OPV devices can be engineered to electrically stimulate the retina via network‐mediated pathways, in a manner comparable to established neurostimulation approaches. The presented OPV electrodes reliably activate retinal ganglion cells, eliciting consistent spike responses to light pulses within the near‐infrared range. The stimulation onset, spike latency, and response profiles suggest effective faradaic charge injection as a key mechanism for neuronal activation, particularly for longer pulse durations. Moreover, it is shown that both light intensity and pulse duration can be used to finely tune the neural response, offering a high degree of control over retinal ganglion cell activation. Finally, it is proven that D18:Y6 blend is biocompatible in vitro when in direct contact with human induced pluripotent stem cell (iPSC)‐derived retinal organoids and mouse explants. These results validate the photo‐electrical performance and biocompatibility of D18:Y6 OPVs and position them as a viable candidate for next‐generation, minimally invasive retinal prosthetics.
- Open Access
- 2 October 2025
- Published by Springer Nature in Research Square
Retinal Organoid Single-Cell Transcriptomics Reveals Effects of PRPF31 Mutation on Early Müller Glial Activation and Progressive Photoreceptor Degeneration
Retinitis pigmentosa (RP) encompasses a group of inherited retinal disorders characterized by progressive degeneration of rod and cone photoreceptors, leading to vision loss. Among RP subtypes, RP11 is linked to mutations in PRPF31, a key spliceosome component, resulting in retinal cell dysfunction. Although PRPF31 is ubiquitously expressed, its mutations predominantly impact retinal cells, leading to the progressive loss of photoreceptors. Despite significant progress, studies focused on photoreceptor and retinal pigment epithelium dysfunction in late disease stages, leaving early molecular events and the involvement of other retinal cell types unresolved. Moreover, comprehensive single-cell analyses capturing dynamic transcriptional changes across all retinal populations at early and late differentiation stages are still lacking. Using patient-derived Retinal Organoids (ROs), this study investigates the developmental trajectory of PRPF31-RP11 mutation through a series of morphological, functional, molecular and transcriptomics analysis. Our results show that ROs recapitulate in vitro key features of RP, including photoreceptor loss and functional impairment. Single-cell RNA sequencing revealed early Müller glial expansion, retinal ganglion cell stress, and progressive photoreceptor degeneration. Findings identify dysregulated molecular pathways associated with phototransduction, oxidative stress, and inflammation, providing insights into RP11 pathogenesis and potential therapeutic targets.
- 2 October 2025
- Published by Springer Nature in Research Square
Open AccessRetinal Organoid Single-Cell Transcriptomics Reveals Effects of PRPF31 Mutation on Early Müller Glial Activation and Progressive Photoreceptor Degeneration
Retinitis pigmentosa (RP) encompasses a group of inherited retinal disorders characterized by progressive degeneration of rod and cone photoreceptors, leading to vision loss. Among RP subtypes, RP11 is linked to mutations in PRPF31, a key spliceosome component, resulting in retinal cell dysfunction. Although PRPF31 is ubiquitously expressed, its mutations predominantly impact retinal cells, leading to the progressive loss of photoreceptors. Despite significant progress, studies focused on photoreceptor and retinal pigment epithelium dysfunction in late disease stages, leaving early molecular events and the involvement of other retinal cell types unresolved. Moreover, comprehensive single-cell analyses capturing dynamic transcriptional changes across all retinal populations at early and late differentiation stages are still lacking. Using patient-derived Retinal Organoids (ROs), this study investigates the developmental trajectory of PRPF31-RP11 mutation through a series of morphological, functional, molecular and transcriptomics analysis. Our results show that ROs recapitulate in vitro key features of RP, including photoreceptor loss and functional impairment. Single-cell RNA sequencing revealed early Müller glial expansion, retinal ganglion cell stress, and progressive photoreceptor degeneration. Findings identify dysregulated molecular pathways associated with phototransduction, oxidative stress, and inflammation, providing insights into RP11 pathogenesis and potential therapeutic targets.
- Open Access
- 27 March 2025
- Published by Cambridge University Press (CUP) in Expert Reviews in Molecular Medicine
- Vol. 27, 1-31
Exploring organoid and assembloid technologies: a focus on retina and brain
Background: The recent emergence of three-dimensional organoids and their utilization as in vitro disease models confirmed the complexities behind organ-specific functions and unravelled the importance of establishing suitable human models for various applications. Also, in light of persistent challenges associated with their use, researchers have been striving to establish more advanced structures (i.e. assembloids) that can help address the limitations presented in the current organoids. Methods: In this review, we discuss the distinct organoid types that are available to date, with a special focus on retinal and brain organoids, and highlight their importance in disease modelling. Results: We refer to published research to explore the extent to which retinal and brain organoids can serve as potential alternatives to organ/cell transplants and direct our attention to the topic of photostimulation in retinal organoids. Additionally, we discuss the advantages of incorporating microfluidics and organ-on-a-chip devices for boosting retinal organoid performance. The challenges of organoids leading to the subsequent development of assembloid fusion models are also presented. Conclusion: In conclusion, organoid technology has laid the foundation for generating upgraded models that not only better replicate in vivo systems but also allow for a deeper comprehension of disease pathophysiology.
- 27 March 2025
- Published by Cambridge University Press (CUP) in Expert Reviews in Molecular Medicine
- Vol. 27, 1-31
Open AccessExploring organoid and assembloid technologies: a focus on retina and brain
Background: The recent emergence of three-dimensional organoids and their utilization as in vitro disease models confirmed the complexities behind organ-specific functions and unravelled the importance of establishing suitable human models for various applications. Also, in light of persistent challenges associated with their use, researchers have been striving to establish more advanced structures (i.e. assembloids) that can help address the limitations presented in the current organoids. Methods: In this review, we discuss the distinct organoid types that are available to date, with a special focus on retinal and brain organoids, and highlight their importance in disease modelling. Results: We refer to published research to explore the extent to which retinal and brain organoids can serve as potential alternatives to organ/cell transplants and direct our attention to the topic of photostimulation in retinal organoids. Additionally, we discuss the advantages of incorporating microfluidics and organ-on-a-chip devices for boosting retinal organoid performance. The challenges of organoids leading to the subsequent development of assembloid fusion models are also presented. Conclusion: In conclusion, organoid technology has laid the foundation for generating upgraded models that not only better replicate in vivo systems but also allow for a deeper comprehension of disease pathophysiology.
- Open Access
- 4 August 2022
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 23 (15) , 8666
In Vitro Cytotoxicity of D18 and Y6 as Potential Organic Photovoltaic Materials for Retinal Prostheses
Millions of people worldwide are diagnosed with retinal dystrophies such as retinitis pigmentosa and age-related macular degeneration. A retinal prosthesis using organic photovoltaic (OPV) semiconductors is a promising therapeutic device to restore vision to patients at the late onset of the disease. However, an appropriate cytotoxicity approach has to be employed on the OPV materials before using them as retinal implants. In this study, we followed ISO standards to assess the cytotoxicity of D18, Y6, PFN-Br and PDIN individually, and as mixtures of D18/Y6, D18/Y6/PFN-Br and D18/Y6/PDIN. These materials were proven for their high performance as organic solar cells. Human RPE cells were put in direct and indirect contact with these materials to analyze their cytotoxicity by the MTT assay, apoptosis by flow cytometry, and measurements of cell morphology and proliferation by immunofluorescence. We also assessed electrophysiological recordings on mouse retinal explants via microelectrode arrays (MEAs) coated with D18/Y6. In contrast to PFN-Br and PDIN, all in vitro experiments show no cytotoxicity of D18 and Y6 alone or as a D18/Y6 mixture. We conclude that D18/Y6 is safe to be subsequently investigated as a retinal prosthesis.
- 4 August 2022
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 23 (15) , 8666
Open AccessIn Vitro Cytotoxicity of D18 and Y6 as Potential Organic Photovoltaic Materials for Retinal Prostheses
Millions of people worldwide are diagnosed with retinal dystrophies such as retinitis pigmentosa and age-related macular degeneration. A retinal prosthesis using organic photovoltaic (OPV) semiconductors is a promising therapeutic device to restore vision to patients at the late onset of the disease. However, an appropriate cytotoxicity approach has to be employed on the OPV materials before using them as retinal implants. In this study, we followed ISO standards to assess the cytotoxicity of D18, Y6, PFN-Br and PDIN individually, and as mixtures of D18/Y6, D18/Y6/PFN-Br and D18/Y6/PDIN. These materials were proven for their high performance as organic solar cells. Human RPE cells were put in direct and indirect contact with these materials to analyze their cytotoxicity by the MTT assay, apoptosis by flow cytometry, and measurements of cell morphology and proliferation by immunofluorescence. We also assessed electrophysiological recordings on mouse retinal explants via microelectrode arrays (MEAs) coated with D18/Y6. In contrast to PFN-Br and PDIN, all in vitro experiments show no cytotoxicity of D18 and Y6 alone or as a D18/Y6 mixture. We conclude that D18/Y6 is safe to be subsequently investigated as a retinal prosthesis.
- Open Access
- 8 March 2022
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 23 (6) , 2922
Retinal Organoids and Retinal Prostheses: An Overview
Despite the progress of modern medicine in the last decades, millions of people diagnosed with retinal dystrophies (RDs), such as retinitis pigmentosa, or age-related diseases, such as age-related macular degeneration, are suffering from severe visual impairment or even legal blindness. On the one hand, the reprogramming of somatic cells into induced pluripotent stem cells (iPSCs) and the progress of three-dimensional (3D) retinal organoids (ROs) technology provide a great opportunity to study, understand, and even treat retinal diseases. On the other hand, research advances in the field of electronic retinal prosthesis using inorganic photovoltaic polymers and the emergence of organic semiconductors represent an encouraging therapeutical strategy to restore vision to patients at the late onset of the disease. This review will provide an overview of the latest advancement in both fields. We first describe the retina and the photoreceptors, briefly mention the most used RD animal models, then focus on the latest RO differentiation protocols, carry out an overview of the current technology on inorganic and organic retinal prostheses to restore vision, and finally summarize the potential utility and applications of ROs.
- 8 March 2022
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 23 (6) , 2922
Open AccessRetinal Organoids and Retinal Prostheses: An Overview
Despite the progress of modern medicine in the last decades, millions of people diagnosed with retinal dystrophies (RDs), such as retinitis pigmentosa, or age-related diseases, such as age-related macular degeneration, are suffering from severe visual impairment or even legal blindness. On the one hand, the reprogramming of somatic cells into induced pluripotent stem cells (iPSCs) and the progress of three-dimensional (3D) retinal organoids (ROs) technology provide a great opportunity to study, understand, and even treat retinal diseases. On the other hand, research advances in the field of electronic retinal prosthesis using inorganic photovoltaic polymers and the emergence of organic semiconductors represent an encouraging therapeutical strategy to restore vision to patients at the late onset of the disease. This review will provide an overview of the latest advancement in both fields. We first describe the retina and the photoreceptors, briefly mention the most used RD animal models, then focus on the latest RO differentiation protocols, carry out an overview of the current technology on inorganic and organic retinal prostheses to restore vision, and finally summarize the potential utility and applications of ROs.